ASTELLAS Financial Statements From 2010 to 2025
| YPHA Stock | EUR 8.80 0.05 0.57% |
Check ASTELLAS PHARMA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ASTELLAS PHARMA's main balance sheet or income statement drivers, such as , as well as many indicators such as . ASTELLAS financial statements analysis is a perfect complement when working with ASTELLAS PHARMA Valuation or Volatility modules.
ASTELLAS |
ASTELLAS PHARMA UNSPADR Company Price To Earning Analysis
ASTELLAS PHARMA's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current ASTELLAS PHARMA Price To Earning | 28.51 X |
Most of ASTELLAS PHARMA's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ASTELLAS PHARMA UNSPADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, ASTELLAS PHARMA UNSPADR has a Price To Earning of 28.51 times. This is 10.33% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. This indicator is about the same for all Germany stocks average (which is currently at 28.72).
ASTELLAS PHARMA UNSPADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ASTELLAS PHARMA's current stock value. Our valuation model uses many indicators to compare ASTELLAS PHARMA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ASTELLAS PHARMA competition to find correlations between indicators driving ASTELLAS PHARMA's intrinsic value. More Info.ASTELLAS PHARMA UNSPADR is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.65 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for ASTELLAS PHARMA UNSPADR is roughly 1.53 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ASTELLAS PHARMA's earnings, one of the primary drivers of an investment's value.About ASTELLAS PHARMA Financial Statements
ASTELLAS PHARMA stakeholders use historical fundamental indicators, such as ASTELLAS PHARMA's revenue or net income, to determine how well the company is positioned to perform in the future. Although ASTELLAS PHARMA investors may analyze each financial statement separately, they are all interrelated. For example, changes in ASTELLAS PHARMA's assets and liabilities are reflected in the revenues and expenses on ASTELLAS PHARMA's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ASTELLAS PHARMA UNSPADR. Please read more on our technical analysis and fundamental analysis pages.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15455 people.
Currently Active Assets on Macroaxis
Other Information on Investing in ASTELLAS Stock
ASTELLAS PHARMA financial ratios help investors to determine whether ASTELLAS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ASTELLAS with respect to the benefits of owning ASTELLAS PHARMA security.